Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke

Status Completed

Clinical Trial Summary

Objective - to assess the effect of Cytoflavin® and its tolerability within the integrated program of rehabilitation of patients who underwent ischemic stroke

Clinical Trial Description

Cerebral stroke (CS) remains one of the key issues of modern society, being a predominant cause of deep and persistent disability of the population. Huge social and economic damage arising from cerebrovascular diseases raises the problem of improving medical care for strokes among the most relevant scientific and practical tasks of neurology Regulation of energy metabolism is considered a powerful tool for acute conditions relief, including those that occur due to acute impairment of cerebral blood flow. A number of adjuvant energy protector concomitant medications with systemic pharmacodynamic properties based on signaling (hormonal) and substrate mode of action of succinic acid and other mitochondrial substrates and co-factors was created for this A significant role in the rehabilitation of patients who underwent CS is assigned to the treatment of complications of care in the intensive care unit, the so-called post-intensive care syndrome (PICS), which is a set of somatic, neurological, social and psychological consequences of periods in intensive care unit (ICU) conditions that bring limitations to the patient's daily activities In the Brain Institute Clinic (Ekaterinburg), the first results of the metabolic status monitoring during physical and cognitive exercise in patients with PICS were obtained. These results prove that control over metabolic state holds the promise of developing approaches to increasing exercise tolerance Taking into account the effectiveness of Cytoflavin® in treatment of acute impairment of cerebral circulation and consequences of cerebrovascular diseases, on the one hand, and its classification as a metabotropic energy corrector, on the other hand, the evaluation of Cytoflavin® medication tolerability in the integrated program of neurorehabilitation of patients with PICS after ischemic stroke presents a significant interest. ;

Study Design

Related Conditions & MeSH terms

Ischemia
Ischemic Stroke
Post Intensive Care Unit Syndrome
Stroke
Syndrome

Clinical Trial Details

NCT number	NCT04194229
Study type	Observational
Source	POLYSAN Scientific & Technological Pharmaceutical Company
Contact
Status	Completed
Phase
Start date	November 11, 2016
Completion date	January 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05196659` - Collaborative Quality Improvement (C-QIP) Study	N/A
Recruiting	`NCT06027788` - CTSN Embolic Protection Trial	N/A
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT05518305` - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting	`NCT06029959` - Stroke and CPAP Outcome Study 3	N/A
Recruiting	`NCT03728738` - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke	Phase 3
Terminated	`NCT03396419` - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting	`NCT05065216` - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)	Phase 2/Phase 3
Recruiting	`NCT04897334` - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke	N/A
Not yet recruiting	`NCT06462599` - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting	`NCT06026696` - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting	`NCT06032819` - Differentiating Between Brain Hemorrhage and Contrast
Recruiting	`NCT02910180` - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed	`NCT02922452` - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT03554642` - Walkbot Robotic Training for Improvement in Gait	Phase 3
Withdrawn	`NCT01866189` - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke	N/A
Recruiting	`NCT03041753` - Reperfusion Injury After Stroke Study	N/A
Completed	`NCT02549846` - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial	Phase 4
Completed	`NCT01678534` - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial	Phase 2
Completed	`NCT02610803` - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke Survivors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms